Multicenter feasibility study of combination therapy with fluorouracil, leucovorin and paclitaxel (FLTAX) for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake

Japanese Journal of Clinical Oncology

Volumn 42, Issue 9, 2012, Pages 787-793

  Iwasa, Satoru ^a   Goto, Masahiro ^b   Yasui, Hirofumi ^c   Nishina, Tomohiro ^d   Takahari, Daisuke ^e   Nakayama, Norisuke ^f   Taira, Koichi ^g   Kusaba, Hitoshi ^h   Fuse, Nozomu ⁱ   Hironaka, Shuichi ^j   Shimada, Yasuhiro ^j   Nakajima, Takako Eguchi ^k  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

^c SHIZUOKA CANCER CENTER   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

^f KANAGAWA CANCER CENTER   (Japan)

^g OSAKA CITY GENERAL HOSPITAL   (Japan)

^h KYUSHU UNIVERSITY   (Japan)

ⁱ NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^j CHIBA CANCER CENTER   (Japan)

^k ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Ascites; Fluorouracil; Gastric cancer; Paclitaxel; Peritoneal metastasis

Indexed keywords

CAPECITABINE; CHLORPHENIRAMINE; CISPLATIN; DEXAMETHASONE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; METHOTREXATE; PACLITAXEL; RANITIDINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC REACTION; ANOREXIA; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DIARRHEA; DIETARY INTAKE; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERSENSITIVITY REACTION; HYPOKALEMIA; HYPONATREMIA; INFECTION; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERITONEUM METASTASIS; PNEUMONIA; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; SENSORY NEUROPATHY; SIDE EFFECT; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASCITES; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EATING; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; HUMANS; INTESTINAL PERFORATION; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PACLITAXEL; PERITONEAL NEOPLASMS; STOMACH NEOPLASMS;

EID: 84865574040     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hys111     Document Type: Article

References (16)

1. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008;9:215-21.
2. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomized phase III noninferiority trial. Ann Oncol 2009;20:666-73.
3. Shirao K, Boku N, Yamada Y, et al. Randomized phase III study of 5-fluorouracil continuous infusion (5FUci) versus methotrexate and 5-FU sequential therapy (MF) in gastric cancer with peritoneal metastasis (JCOG0106). J Clin Oncol 2009;27:15s (Suppl; Abstr 4545).
4. Sawaki A, Yamaguchi K, Nabeya Y, et al. 5-FU/l-LV (RPMI) versus S-1 as first-line therapy in patients with advanced gastric cancer: a randomized phase III non-inferiority trial (ISO-5FU10 Study Group trial). Eur J Cancer Suppl 2009;7:363.
5. Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009;10:1063-9.
6. Matsubara J, Shimada Y, Takashima A, et al. A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer. Jpn J Clin Oncol 2008;38:540-6.
7. Matsubara J, Shimada Y, Kato K, et al. Phase II study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel as first-line therapy for advanced gastric cancer. Oncology 2011;81:291-7.
8. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
9. Yamao T, Shimada Y, Shirao K, et al. Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Trial. Jpn J Clin Oncol 2004;34:316-22.
10. Imamoto H, Oba K, Sakamoto J, et al. Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions: a multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer. Gastric Cancer 2011;14:81-90.
11. Oh SY, Kwon HC, Lee S, et al. A phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. Jpn J Clin Oncol 2007;37:930-5.
12. Narahara H, Iishi H, Imamura H, et al. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/ TOP-002). Gastric Cancer 2011;14:72-80.
13. Fujii M, Kim YH, Satoh T, et al. Randomized phase III study of S-1 alone versus S-1 plus docetaxel (DOC) in the treatment for advanced gastric cancer (AGC): the START trial update. J Clin Oncol 2011;29 (Suppl; Abstr 4016).
14. Iwasa S, Nakajima TE, Nakamura K, et al. First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer. Gastric Cancer 2011;15:21-6.
15. Takiuchi H, Fukuda H, Boku N, et al. Randomized phase II study of best-available 5-fluorouracil (5-FU) versus weekly paclitaxel in gastric cancer (GC) with peritoneal metastasis (PM) refractory to 5-FU-containing regimens (JCOG0407). J Clin Oncol 2010;28:15s (Suppl; Abstr 4052).
16. Shitara K, Ito S, Sawaki A, et al. Improvement of oral intake following chemotherapy in gastric cancer patients with an inability to eat. Oncology 2010;79:211-8.